Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount
Menarini Remains In Front
Executive Summary
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.
You may also be interested in...
Five Potential Blockbuster Oncology Approvals To Look Out For In 2023
With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.
Priority Review Sets Up Sanofi’s ‘Best In Disease’ Hemophilia Drug For 2023 Launch
Sanofi can now expect an FDA decision in early 2023 on efanesoctocog, setting it up for a battle with Roche’s Hemlibra and BioMarin’s gene therapy Roctavian, which was just approved in the EU.
Roche's SERD Setback Means Menarini Retains An Edge
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.